Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 18 citing articles:

Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies
Yonatan Moges Mesfin, Joseph E. Blais, Kelemu Tilahun Kibret, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 9, pp. 2119-2131
Open Access | Times Cited: 4
Cost-effectiveness of nirmatrelvir/ritonavir in COVID-19 patient groups at high risk for progression to severe COVID-19 in the Netherlands
Carlos Duarte, Michel L. Peters, Michelle H. M. de Goeij, et al.
Cost Effectiveness and Resource Allocation (2025) Vol. 23, Iss. 1
Open Access
A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus
Mickie Cheng, Alex Mann, Brian M. Maas, et al.
Pulmonary Therapy (2025)
Open Access
Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis
Sien Ombelet, Diego Castanares‐Zapatero, Fabian Desimpel, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 2
Open Access | Times Cited: 3
Cardiovascular adverse effects of antiviral therapies for COVID-19: Evidence and plausible mechanisms
Eileen Chen, Lei Xi
Acta Pharmacologica Sinica (2024)
Open Access | Times Cited: 3
Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
Ioannis Karniadakis, Nikolaos Mazonakis, Constantinos Tsioutis, et al.
Infectious Disease Reports (2023) Vol. 15, Iss. 6, pp. 662-678
Open Access | Times Cited: 7
Impact factors of Blastocystis hominis infection in persons living with human immunodeficiency virus: a large-scale, multi-center observational study from China
Shun-Xian Zhang, Jichun Wang, Zhongwei Li, et al.
Infectious Diseases of Poverty (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 6
Nirmatrelvir/Ritonavir Use and Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-Risk Population With COVID-19: A Matched Cohort Study
Adeel A. Butt, Yan Peng, Obaid S. Shaikh, et al.
The Journal of Infectious Diseases (2023) Vol. 229, Iss. 1, pp. 147-154
Open Access | Times Cited: 4
Comparison between available early antiviral treatments in outpatients with SARS-CoV-2 infection: a real-life study
Matteo Rinaldi, Caterina Campoli, Mena Gallo, et al.
BMC Infectious Diseases (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Characteristics and outcome of a territory-wide cohort study of patients with acquired hemophilia A in Hong Kong
Chun-fung Sin, Ting Hon Stanford Li, Ka-ping Wong, et al.
Thrombosis Research (2023) Vol. 233, pp. 138-144
Open Access | Times Cited: 4
Comparing the effectiveness of molnupiravir and nirmatrelvir‐ritonavir in non‐hospitalized and hospitalized COVID‐19 patients with type 2 diabetes: A target trial emulation study
Eric Yuk Fai Wan, Zoey C. T. Wong, Vincent Ka Chun Yan, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4653-4664
Closed Access | Times Cited: 1
Azvudine efficacy in reducing mortality in COVID-19 patients
Zhen Zhong, Xiaofeng Liu, Xiaozhong Zhou, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 1
Azvudine reduces the mortality rate of patients with Coronavirus disease 2019: a single-center retrospective analysis study
Zhen Zhong, Xiaofeng Liu, Xiaozhong Zhou, et al.
Research Square (Research Square) (2024)
Open Access
EFFECTS OF ANTIVIRAL THERAPEUTIC DRUGS FOR SARS-COV-2 ON TREATMENT OUTCOMES AND CLINICAL PARAMETERS
Abdul Bari, Atiqullah Sarwari, Mohammad Hassan, et al.
Eurasian Journal of Ecology (2024) Vol. 79, Iss. 2, pp. 136-146
Open Access
Expert consensus on the clinical application of oral small-molecule antiviral drugs against COVID-19

Infectious Diseases & Immunity (2024)
Open Access
Real clinical effectiveness of molnupiravir against 30-day mortality among 74 541 SARS-CoV-2 positive patients: a nationwide cohort study from the Czech Republic
Tomáš Pavlík, Jiří Jarkovský, Ondřej Šanca, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 12
Open Access
Association among diabetes, cardiovascular disease and mortality in patients hospitalised for COVID-19: an analysis of the American Heart Association COVID-19 CVD Registry
Unjali P. Gujral, Lauren T Vanasse, Abhinav Goyal, et al.
BMJ Open (2024) Vol. 14, Iss. 12, pp. e084087-e084087
Open Access
Evaluation of the efficacy and safety of nirmatrelvir/ritonavir co-administration inpatients with rheumatic disease infected with SARS-CoV-2: a real-world study
Xue Zhong, Chao Wang, Lin Huang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access
Page 1

Scroll to top